Ann: FY18 Full Year Results - Investor Presentation, page-33

First 33 Last

Share
Profile

Follow
LightForce

2,917 Posts.

188

21/08/18

08:29

Post #: 35052179
Share

Originally posted by jord@n ↑

I've had some time to digest and review the results.

View attachment 1248995

Firstly, if we look at revenue growth, this has dropped dramatically over the years from high double-digits (when we were trading above 20 p/e) to the second consecutive year of single-digit growth (whilst trading around 10-15 p/e range).

During this time sales growth has dropped slightly as well but managed to be mostly stable during the last few years. We're told so far this year group sales growth has been 5.9%, which is promising considering we've been under 5% growth the last few years. I'll give new management the benefit of the doubt to hit 5% sales growth for FY19.

Looking at the margin, this has also dropped from mid 50%'s to high 40%'s over the last few years. I'd like to see this stabilize or push back into the 50%'s.

Another standout for me was the high increase in CODB for their vets, jumping from 64% to almost 69%; resulting in EBITDA declining this year by 5m.

I'm happy with the opportunities and strategies that management are looking to improve the business. However, until I see some more signs these are successful, I'm wary to invest in a sinking ship (which is how this report paints GXL).

I'm happy with the dividend cut, however now that leaves us with a 2.5% annual dividend. The upside is management can deliver and that should see us close to $5 likely by HY19 if a nice update is provided. The downside risk is management under-deliver and that will see us float I suspect around $3.5-$4 pending no takeover offer etc (whilst enjoying the div for holding). Given current valuation and the fact that new management has not yet proven themselves, I'll be waiting for the price to drop further to initiate a position. I don't see this going back to $4.50 levels until more evidence is shown to confirm delivering on their strategy.

Expand

How did you evaluate the gross margin for FY18? How did you adjust it down from 56.3% to 47.9%? By including all the exceptional items? Also, how do you estimate the profit to be $35M? You should substantiate how you got to $35M before you throw these numbers to the forum.

GXL Price at posting: $4.14 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

HotCopper Highlights: Your most watched stocks for Week 47, 2024

SIG

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

LPE

Sales growth pushes Lovisa's fortunes (and shares) upwards

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

There are more pages in this discussion • 7 more messages in this thread...

First 33 Last

Add GXL (ASX) to my watchlist

Ann: FY18 Full Year Results - Investor Presentation, page-33

Top Stories

HotCopper Highlights: Your most watched stocks for Week 47, 2024

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Sales growth pushes Lovisa's fortunes (and shares) upwards

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

Featured News